MIRA
INFORM REPORT
|
Report Date : |
22.12.2008 |
IDENTIFICATION DETAILS
|
Name : |
KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS |
|
|
|
|
Registered Office : |
307 - Wahab Arcade, |
|
|
|
|
Country : |
|
|
|
|
|
Year of Establishment : |
1998 |
|
|
|
|
Legal Form : |
Partnership |
|
|
|
|
Line of Business : |
Manufacture and
Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Status : |
Small Concern |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Business Name
KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS
Full Address
|
Registered Address |
|
307
- Wahab Arcade, |
|
Tel |
92 (21) 2626625, 2626474 |
|
Fax |
92 (21) 2629654 |
|
|
krka-pak@cyber.net.pk |
Short Description Of Business
|
Nature of Business |
Manufacture &
Marketing of Pharmaceutical Products |
|
Year Established |
1998 |
|
National Tax # |
2611725 |
Factory Location
|
Address |
Plot # 25/2, Sector 12-C, North Karachi Industrial Area, |
|
Tel # |
92 (21) 6954523 |
|
Fax # |
92 (21) 6951802 |
Legal Status
Subject Company was established as a Partnership business in 1998
Details of Management
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. S. Muhammad Ahmed Mr. Shakil Ahmed Chandna Mr. Nadeem Ahmed Chandna Mr. Tasneem Akhter Mr. Jawed Akhter Mr. Asif Naqi |
Pakistani Pakistani Pakistani Pakistani Pakistani Pakistani |
307 - Wahab Arcade, 307 - Wahab Arcade, 307 - Wahab Arcade, 307 - Wahab Arcade, 307 - Wahab Arcade, 307 - Wahab Arcade, |
Business Business Business Business Business Business |
Managing Partner Partner Partner Partner Partner Partner |
Associates
A. Subsidiary
None
B. Associated Companies
- Do -
Products
(1) Subject Company is engaged in manufacture & marketing of Pharmaceutical Products.
(2) It purchases raw material against D/A, L/C basis.
(3) Its’ major customers are Distributors, Traders, Pharmacies
& Hospitals located in
(4) Subject operates from caption leased factory premises of area measuring 3,000 Sq.Yard. which is situated in industrial area.
(5) Subject employs about 65 persons in its set up.
Products
ALLERMINE, AMMOTUS, ANTASIL,
APAURIN, BENAQUIN, BINIPLEX, CHLORAMPHENICOL, CINIL, CORBIC, DIURALKA, EFLARAN,
EGOCIN, ELENIUM, ELZIN, EPHEDRINE, GENTAMYCIN, INSTANT ENEMA, KANADEX,
KANADEX-N, KANAMIDE, KANAMOL,
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2007 |
60,000,000/- (Estimated) |
Capacity & Production
The capacity and production of the company’s plant is indeterminable as it is multi- product and involves various processes of manufacture.
Trade Suppliers (Foreign)
(1) PURAC
(2) NORTH
(3)
(4) ROYAL
(5) WUHAN
YUANCHENG TECHNOLOGY DEVELOPMENT CO LTD,
Authorized Distributors
Mainly in
Bankers
United Bank Ltd,
(2) MCB Bank
Limited,
Memberships
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 79.00 |
|
|
1 |
Rs. 119.10 |
|
Euro |
1 |
Rs. 110.60 |
Comments
Subject Company was established in 1998 and is engaged in
manufacture & marketing of Pharmaceutical Products.
Trade relations are reported as fair. Company can be considered for
normal business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.47.39 |
|
|
1 |
Rs.70.65 |
|
Euro |
1 |
Rs.66.33 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)